SAN DIEGO, March 22 /PRNewswire/ -- Trega Biosciences, Inc. (Nasdaq: TRGA)
today announced the addition of Bruce L.A. Carter, Ph.D. to its Board of
Directors. Dr. Carter fills a vacant position on the Board as a Class II
director with a term expiring in 2002.
Dr. Carter currently serves as Corporate Executive Vice President and
Chief Scientific Officer at Novo Nordisk located in Denmark where he is
responsible for their global research strategy and external healthcare
collaborations. In addition, he is President of ZymoGenetics, Inc.
Previously, he was Head of Molecular Genetics at G.D. Searle & Co., Ltd. Dr.
Carter serves as director on the Boards of ZymoGenetics, AVI BioPharma and
Skeletech.
"I am delighted that Bruce has joined our Board," said Michael G. Grey,
president and chief executive officer. "He brings to Trega expertise from his
experience in both the pharmaceutical and biotechnology arenas. He is a
business leader as well as a respected scientist and Trega should benefit
greatly from his contribution."
Trega Biosciences is an information-driven company focused on accelerating
drug discovery from disease targets to clinical candidates through its
iDiscovery(TM) technologies. These technologies, comprised of information-
rich small molecule combinatorial chemistry and in vitro assays coupled with
predictive models and proprietary databases, are designed to rapidly create
novel drug candidates having greater chances of clinical success. Trega's
iDiscovery(TM) technologies span the drug discovery process, beginning with
the creation of novel compounds to the delivery of uniquely qualified drug
leads to the pharmaceutical and life science industries.
Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that involve
risks and uncertainties, including whether the reported transition within the
Board will occur without disrupting Trega's business and operations, whether
any proposed product can be successfully formulated, scaled-up, developed, and
commercialized, whether regulatory approvals can be obtained, the impact of
competitive products and pricing, the financial condition of Trega in the
future, whether any collaborations or alliances will be successful, and other
risks detailed from time to time in Trega's Securities and Exchange Commission
filings. These forward-looking statements represent Trega's judgment as of
the date of this release. Actual results may differ materially from those
projected. Trega disclaims, however, any intent or obligation to update these
forward-looking statements.
Trega's releases are on the World Wide Web at http://www.trega.com and PR
Newswire's fax-on-demand service at 1-800-758-5804, extension 374050.
SOURCE Trega Biosciences, Inc.
 back to top
Related links:
http://www.trega.com
Company News On-Call:
http://www.prnewswire.com/comp/374050.html or fax,
800-758-5804, ext. 374050
CONTACT:
Gerard A. Wills, Vice President, Finance &
CFO, 858-410-6695, or Cynthia Reindal, Communications & Investor
Relations, 858-410-6601, both of Trega Biosciences, Inc.
|
